Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiac dysfunction associated with trastuzumab.

Karen Lisa Smith1, Chau Dang, Andrew D Seidman

  • 1Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

Expert Opinion on Drug Safety
|August 16, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Withdrawal of Guideline-Directed Medical Therapy in Heart Failure With Improved Ejection Fraction: A Systematic Review and Meta-Analysis With Trial Sequential Analysis.

JACC. Heart failure·2026
Same author

Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer.

Breast cancer research and treatment·2025
Same author

NCCN Guidelines® Insights: Breast Cancer, Version 5.2025.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

Rare Case of a Complex Coronary Triad Repaired via Axillary Thoracotomy in an Infant.

JACC. Case reports·2025
Same author

Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis: A Randomized Clinical Trial.

JAMA oncology·2025
Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026
Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026
Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026
Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026
Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026
See all related articles

Trastuzumab, an antibody targeting HER2-positive breast cancer, improves survival but can cause cardiac toxicity. Cardiac monitoring is now standard in clinical trials to manage this side effect.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • HER2/neu gene amplification occurs in ~25% of breast cancers, driving tumor progression.
  • Trastuzumab is a HER2-targeted therapy improving outcomes in HER2-positive breast cancer.
  • Cardiac toxicity is an identified adverse event associated with trastuzumab therapy.

Purpose of the Study:

  • To review cardiac toxicity findings in key trastuzumab clinical trials.
  • To describe the clinical characteristics of trastuzumab-associated cardiac toxicity.

Main Methods:

  • Review of pivotal Phase III clinical trials of trastuzumab.
  • Analysis of reported cardiac toxicity data.
  • Characterization of clinical presentation and risk factors.

Related Experiment Videos

Main Results:

  • Trastuzumab significantly improves survival and reduces recurrence in HER2-overexpressing breast cancer.
  • Cardiac toxicity emerged as an unexpected adverse event in early trials.
  • Prospective cardiac monitoring is now integrated into trastuzumab trials.

Conclusions:

  • Trastuzumab is effective for HER2-positive breast cancer but requires cardiac monitoring.
  • Understanding trastuzumab-associated cardiac toxicity is crucial for patient management.
  • Ongoing research and monitoring are essential for safe and effective HER2-targeted therapy.